Probiotisch Onderzoek: Open-label Functionele Interventie en Longitudinale Evaluatie bij Gezonde Volwassenen (PROFILE)
This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.
During the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.
This study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Research Team
- Telefoonnummer: +44 7757 056785
- E-mail: team@healthspanbiotics.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aged 18 years or older at the time of providing informed consent.
- In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.
- No history of significant psychiatric or neurological illness
- Ability to complete study specific tasks, including:
- Daily oral intake of a probiotic capsule
- Self-collection of stool samples
- Completion of online questionnaires and simple cognitive tasks
- Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.
- Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.
Exclusion Criteria:
- Participants will be excluded from the study if any of the following criteria apply:
- Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:
- β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals
- Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:
- Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.
- A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.
- Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.
- Major gastrointestinal disease or surgery:
- Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.
- Current pregnancy or development of pregnancy, breastfeeding
- Known allergy to probiotic or compounding ingredients:
- Vitamin D3
- Isomaltooligosaccharide
- Yeast extract
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Short Phase Group
This group will receive supplementation for 1 month |
This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked. |
|
Experimenteel: Long Phase Group
This group will receive supplementation for 6 months |
This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Changes in metagenome of stool samples
Tijdsspanne: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
|
The investigators will evaluate changes in genetic material in participant stool, representing establishment of the probiotic in the digestive tract |
From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in blood multiome
Tijdsspanne: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
|
This measure will evaluate change in blood proteins (plasma proteome) and blood metabolites (plasma metabolome). Both measures are quantified using mass to charge ratio. |
From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
|
|
Changes in cognition
Tijdsspanne: Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.
|
Participants will complete a weekly online cognitive test administered via our remote platform. This generates a score relativised to each participant's performance, and does not utilise a scale. |
Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.
|
|
Change in daytime sleepiness
Tijdsspanne: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
Participants will complete the Epworth Sleepiness Scale (ESS), with a minimum score of 0, and a maximum score of 24. A higher score indicates worse daytime sleepiness. |
Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
|
Change in sleep quality
Tijdsspanne: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
Participants will complete the Pittsburgh Sleep Quality Index (PSQI) survey. This has a minimum global score of 0, and a maximum of 21. A higher score indicates worse sleep quality. |
Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
|
Change in self-reported wellbeing and mood
Tijdsspanne: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
Participants will fill out a questionnaire at the beginning and end of the study which will ask questions about subjective mood and wellbeing. |
Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
|
|
Adverse event monitoring
Tijdsspanne: Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.
|
Participants will be expected to self-report any adverse features resulting from use of the supplement |
Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PROFILE
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
All personal data collected during the study will be pseudonymised at the earliest possible stage. Each participant will be assigned a unique study ID number, which will be used on all samples, questionnaires, and datasets. A separate, password-protected file will securely store the link between participant names and study IDs. This file will be accessible only to authorised study personnel.
No identifiable personal information will be included in the research database or shared with external analysts. All electronic data will be stored on secure, encrypted servers in compliance with UK GDPR and the Data Protection Act 2018. Access will be limited to members of the research team through password-protected accounts and role-based permissions.
Hard copies of personal data will not be collected or stored. Any correspondence containing identifiable information (e.g. email addresses) will be deleted or anonymised once no longer needed.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .